Free Trial

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.1386 of 5 stars
$15.132.9%N/A-5.39Buy$33.62
Ultragenyx Pharmaceutical (RARE)
4.6637 of 5 stars
$29.940.8%N/A-5.40Moderate Buy$81.50
Sarepta Therapeutics (SRPT)
4.5985 of 5 stars
$22.000.9%N/A-25.19Hold$43.63
Pfizer (PFE)
4.9702 of 5 stars
$25.140.0%6.84%13.38Hold$28.12
Exelixis (EXEL)
4.8709 of 5 stars
$38.490.5%N/A18.53Moderate Buy$44.06
Moderna (MRNA)
4.5531 of 5 stars
$28.050.1%N/A-3.73Hold$43.59
United Therapeutics (UTHR)
4.9156 of 5 stars
$313.610.2%N/A12.26Moderate Buy$382.00
Biogen (BIIB)
4.8617 of 5 stars
$138.790.1%N/A13.30Hold$185.74
Sanofi (SNY)
3.9549 of 5 stars
$49.850.2%3.21%11.98Buy$62.00
Eli Lilly and Company (LLY)
4.9986 of 5 stars
$703.610.3%0.85%46.10Moderate Buy$950.17
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Palantir’s Soaring Valuation—Justified or Overhyped?
3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines